SCHEMBL3608656

SCHEMBL3608656

COc1ccc(Nc2nc(-c3sc(NC(=N)N)nc3C)cs2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.76
GAA P10253 7/20 0.76
ALDH1A1 P00352 5/20 0.76
HPGD P15428 4/20 0.76
LMNA P02545 3/20 0.76
MEN1 O00255 10/20 0.72
KMT2A Q03164 10/20 0.72
NPC1 O15118 4/20 0.72
TSHR P16473 3/20 0.72
HSD17B10 Q99714 3/20 0.72
TDP1 Q9NUW8 3/20 0.72
POLB P06746 3/20 0.69
KDM4E B2RXH2 3/20 0.58
HTT P42858 3/20 0.58
USP2 O75604 2/20 0.58
ALOX15 P16050 1/20 0.58
GFER P55789 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
SMN1; SMN2 Q16637 4/20 0.56
PPARG P37231 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3604078 0.89 PLAU (0.61) MAPTGAAALDH1A1HPGDLMNA
SCHEMBL3595812 0.88 MEN1 (0.69) MAPTGAAALDH1A1HPGDLMNA
SCHEMBL8226945 0.88 MEN1 (0.65) MAPTGAAALDH1A1HPGDLMNA
SCHEMBL4533727 0.87 GAA (0.98) MAPTGAAALDH1A1HPGDLMNA
SCHEMBL3614813 0.85 TRPV4 (0.68) MAPTGAAALDH1A1HPGDLMNA
SCHEMBL4160940 0.84 ALDH1A1 (0.78) MAPTGAAALDH1A1HPGDLMNA
SCHEMBL16434540 0.83 MEN1 (0.97) MAPTGAAALDH1A1HPGDLMNA
SCHEMBL3607067 0.82 MEN1 (0.73) MAPTGAAALDH1A1HPGDLMNA
SCHEMBL3615884 0.78 PI4KB (0.51) MAPTGAAALDH1A1HPGDLMNA
SCHEMBL5438395 0.77 ALDH1A1 (0.81) MAPTGAAALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US claimed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies GRN, MAPT, GUCY1B1 MAPT 2/4885GAA 91/4885ALDH1A1 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.